| Market Capitalization (Millions $) |
1,678 |
| Shares
Outstanding (Millions) |
147 |
| Employees |
367 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-443 |
| Cash Flow (TTM) (Millions $) |
-85 |
| Capital Exp. (TTM) (Millions $) |
4 |
Business Description
Vir Biotechnology Inc is a clinical-stage immunology company focused on developing therapies to treat infectious diseases.
The company was founded in 2016 by George Scangos, a former CEO of Biogen.
The company has its headquarters in San Francisco, California and operates in the United States and the United Kingdom.
Vir is focused on developing treatments for viral infections such as hepatitis B virus, respiratory syncytial virus (RSV), influenza, and novel coronaviruses like SARS-CoV-2.
The company is looking to leverage its expertise in immunology and virology to develop novel treatments that can improve patient outcomes and reduce the spread of infectious diseases.
Vir has a diverse pipeline of product candidates, including monoclonal antibodies, antivirals, and vaccines, that are being developed for a range of viral infections.
The company has several partnerships and collaborations with leading pharmaceutical companies, including GlaxoSmithKline, Biogen, and Alnylam.
Vir has a strong management team and scientific advisory board, comprising experts in virology, immunology, and drug development.
The company has raised over $2 billion in funding to support its research and development efforts.
Overall, Vir Biotechnology Inc is a promising biotech company with a focus on developing innovative treatments for infectious diseases.
With a strong pipeline of product candidates and partnerships with established pharmaceutical companies, the company is well-positioned to make a significant impact in the fight against viral infections.
Company Address: 1800 Owens Street San Francisco 94158 CA
Company Phone Number: 906-4324 Stock Exchange / Ticker: NASDAQ VIR
|
1.11% 
100 %